SCHEMBL24514573

SCHEMBL24514573

COc1ccc(CN2CCC(NC(=O)COc3ccc(-c4ccccc4)cc3)CC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.74
SIGMAR1 Q99720 4/20 0.73
ADIPOR2 Q86V24 1/20 0.69
ADIPOR1 Q96A54 1/20 0.69
USP2 O75604 1/20 0.68
FAAH O00519 3/20 0.65
ACHE P22303 3/20 0.65
BCHE P06276 1/20 0.63
MCHR1 Q99705 5/20 0.60
HRH3 Q9Y5N1 1/20 0.60
DRD4 P21917 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24514563 0.92 POLB (0.86) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL25568935 0.92 POLB (0.74) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL4031641 0.87 POLB (0.70) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL25568937 0.86 POLB (0.66) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL25569213 0.85 POLB (0.70) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL5862230 0.85 SIGMAR1 (1.00) SIGMAR1
SCHEMBL17951031 0.84 MCHR1 (0.68) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL24514196 0.84 ADIPOR2 (0.73) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL17946047 0.84 POLB (0.91) POLBSIGMAR1ADIPOR2ADIPOR1USP2
SCHEMBL24514564 0.83 ADIPOR2 (0.82) POLBSIGMAR1ADIPOR2ADIPOR1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234923-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES TRUSTEES OF TUFTS COLLEGE 2023-07-27 US disclosed
US-11655212-B2 Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes TRUSTEES OF TUFTS COLLEGE (US) 2023-05-23 US disclosed
US-20220185777-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES TRUSTEES OF TUFTS COLLEGE 2022-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655212-B2 Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes ADIPOR1, ADIPOR2, GPR119 POLB 3985/4885SIGMAR1 3904/4885ADIPOR2 2/4885
US-20230234923-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES ADIPOR1, ADIPOR2, GPR119 POLB 3985/4885SIGMAR1 3904/4885ADIPOR2 2/4885
US-20220185777-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES ADIPOR1, ADIPOR2, GPR119 POLB 3985/4885SIGMAR1 3904/4885ADIPOR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.